Martin Gleave

20PUBLICATIONS
127CO-AUTHORS
ChemotherapyMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Pacific Peoples sport and physical activity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jun 02, 2026
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer.

|Aug 04, 2025
New frontiers in prostate cancer treatment from systemic therapy to targeted therapy.

Shaghayegh Nouruzi, Maxim Kobelev, Nakisa Tabrizian

|May 29, 2025
Author Correction: Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis.

Amal M El-Naggar, Syam Prakash Somasekharan, Yemin Wang

|May 09, 2025
Identifying Rare Germline Variants Associated with Metastatic Prostate Cancer Through an Extreme Phenotype Study.

Yen-Yi Lin, Hamideh Sharifi Noghabi, Stanislav Volik

|Apr 10, 2025
Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.

Joy C Yang, Pengfei Xu, Shu Ning

|Jan 12, 2025
Developing novel Lin28 inhibitors by computer aided drug design.

Victor M Matias-Barrios, Mariia Radaeva, Graciella Rosellinny

Pageof 4

Frequent Collaborators

7 joint publications

Yuzhuo Wang

4 joint publications

Poul H Sorensen

3 joint publications

Colin Collins

3 joint publications

Htoo Zarni Oo